Synaptogenix to Present Data at Alzheimer's Association International Conference 2021 Highlighting Bryostatin Restores Cognitive Function Above Baseline
Synaptogenix, Inc. (Nasdaq: SNPX) announced that their abstract for Bryostatin-1, a leading candidate for treating Alzheimer's disease, has been accepted at the Alzheimer's Association International Conference from July 26-30, 2021. The poster presentation will discuss how Bryostatin significantly improved cognitive functions in advanced AD patients above their baseline levels. Dr. Daniel Alkon highlighted the promising data from Phase 2 trials, suggesting notable cognitive enhancements compared to placebo controls. Synaptogenix has also explored Bryostatin's efficacy in other neurodegenerative disorders.
- None.
- None.
NEW YORK, July 14, 2021 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that its abstract has been accepted at the Alzheimer's Association International Conference ("AAIC"), which will be held online and in-person July 26-30, 2021.
The Company's lead drug candidate, Bryostatin-1, will be featured in a poster presentation entitled: "Bryostatin Restores Cognitive Functions Above Baseline in Advanced Alzheimer's Disease ("AD") Patients: A Regenerative Therapeutic Strategy."
"Bryostatin improved cognition in patients with advanced Alzheimer's disease significantly above their baseline levels in recently completed data analyses that consolidated all pre-specified patients under identical protocol conditions in our two Phase 2 pilot trials," commented Dr. Daniel Alkon, Synaptogenix's President and Chief Scientific Officer. "We believe the results provide evidence of significant AD patient cognitive improvement – with potential clinically meaningful benefit – at a level not observed with the randomized placebo control patients."
About Synaptogenix, Inc.
Synaptogenix is a clinical-stage biopharmaceutical company that has historically worked to develop novel therapies for neurodegenerative diseases. Synaptogenix has conducted clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's disease. Preclinical studies have also demonstrated Bryostatin's regenerative mechanisms of action for the rare disease, Fragile X syndrome, and for other neurodegenerative disorders such as multiple sclerosis, stroke, and traumatic brain injury. The U.S. Food and Drug Administration has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 as a treatment for Fragile X syndrome. Bryostatin-1 has already undergone testing in more than 1,500 cancer study subjects, thus creating a large safety data base that will further inform clinical trial designs.
Additional information about Synaptogenix, Inc. may be found on its website: www.synaptogen.com.
Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. These forward-looking statements include statements regarding the Phase 2 clinical trial of Bryostatin-1 and further studies, and continued development of use of Bryostatin-1 for AD and other cognitive diseases. Such forward-looking statements are subject to risks and uncertainties and other influences, many of which the Company has no control over. There can be no assurance that the clinical program for Bryostatin-1 will be successful in demonstrating safety and/or efficacy, that we will not encounter problems or delays in clinical development, or that Bryostatin-1 will ever receive regulatory approval or be successfully commercialized. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Additional factors that may influence or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing, the significant length of time associated with drug development and related insufficient cash flows and resulting illiquidity, the Company's patent portfolio, the Company's inability to expand its business, significant government regulation of pharmaceuticals and the healthcare industry, lack of product diversification, availability of the Company's raw materials, existing or increased competition, stock volatility and illiquidity, and the Company's failure to implement its business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the Securities and Exchange Commission. The Company does not undertake to update these forward-looking statements.
Contact information:
Investors and Media
Investor Relations
Brett Maas
Hayden IR
brett@haydenir.com
(646)536-7331
Robert Weinstein
Chief Financial Officer
Synaptogenix, Inc.
rweinstein@synaptogen.com
View original content:SOURCE Synaptogenix, Inc.
FAQ
What is the key announcement from Synaptogenix on July 14, 2021?
What drug is Synaptogenix presenting at the Alzheimer's conference?
What were the results of the Phase 2 trials for Bryostatin-1?
Who is the President of Synaptogenix and what did he say about Bryostatin?
What other diseases has Bryostatin-1 been tested for?
